5 Key Takeaways

• 1

  The iValve prototypes reduced regional backflow velocity spikes, indicating potential to lessen lifelong anticoagulation therapy needs.

• 2

  The study evaluated the iValve's performance, designed to combine durability of mechanical heart valves with hemodynamic advantages of bioprosthetic valves.

• 3

  Current mechanical heart valves require lifelong anticoagulation due to nonphysiological flow patterns, posing risks of bleeding and thromboembolism.

• 4

  The iValve's design includes a saddle-shaped housing and eye-like leaflets, optimizing blood flow and reducing thrombotic risk.

• 5

  Top-performing iValve prototypes achieved a mean regional backflow velocity of −4.34 m/s, outperforming existing mechanical heart valves.